Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Z Li

Showing results (121-130 of 270) with videos related to

Pageof 27
Sort By:
Medrxiv : the Preprint Server for Health Sciences|March 30, 2023
Statistical Challenges when Analyzing SARS-CoV-2 RNA Measurements Below the Assay Limit of Quantification in COVID-19 Clinical TrialsCarlee B Moser, Kara W Chew, Mark J Giganti, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 18, 2020
A minor population of macrophage-tropic HIV-1 variants is identified in recrudescing viremia following analytic treatment interruptionViviane M Andrade, Carla Mavian, Dunja Babic, et al.
Kidney International Reports|September 20, 2021
Nicotinamide Adenine Dinucleotide Biosynthetic Impairment and Urinary Metabolomic Alterations Observed in Hospitalized Adults With COVID-19-Related Acute Kidney InjuryNathan H Raines, Matthew D Cheung, Landon S Wilson, et al.
The Journal of Clinical Investigation|January 29, 2019
Intact HIV-1 proviruses accumulate at distinct chromosomal positions during prolonged antiretroviral therapyKevin B Einkauf, Guinevere Q Lee, Ce Gao, et al.
The Journal of Infectious Diseases|October 14, 2024
Viral and Symptom Rebound Following Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Therapy in a Randomized Placebo-Controlled TrialKara W Chew, Brooke McGinley, Carlee Moser, et al.
Eclinicalmedicine|September 10, 2024
Post-acute COVID-19 outcomes including participant-reported long COVID: amubarvimab/romlusevimab versus placebo in the ACTIV-2 trialTeresa H Evering, Carlee Moser, Nikolaus Jilg, et al.
Mbio|February 24, 2021
Phospholipid Metabolism Is Associated with Time to HIV Rebound upon Treatment InterruptionLeila B Giron, Emmanouil Papasavvas, Xiangfan Yin, et al.
Medrxiv : the Preprint Server for Health Sciences|June 14, 2021
Virologic features of SARS-CoV-2 infection in childrenLael M Yonker, Julie Boucau, James Regan, et al.
The Journal of Infectious Diseases|October 14, 2021
Virologic Features of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in ChildrenLael M Yonker, Julie Boucau, James Regan, et al.
The Journal of Antimicrobial Chemotherapy|March 11, 2021
Impact of pre-existing drug resistance on risk of virological failure in South AfricaJonathan Z Li, Natalia Stella, Manish C Choudhary, et al.
Pageof 27

Showing results (121-130 of 270) with videos related to

Sort By:
Pageof 27
Medrxiv : the Preprint Server for Health Sciences|March 30, 2023
Statistical Challenges when Analyzing SARS-CoV-2 RNA Measurements Below the Assay Limit of Quantification in COVID-19 Clinical TrialsCarlee B Moser, Kara W Chew, Mark J Giganti, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 18, 2020
A minor population of macrophage-tropic HIV-1 variants is identified in recrudescing viremia following analytic treatment interruptionViviane M Andrade, Carla Mavian, Dunja Babic, et al.
Kidney International Reports|September 20, 2021
Nicotinamide Adenine Dinucleotide Biosynthetic Impairment and Urinary Metabolomic Alterations Observed in Hospitalized Adults With COVID-19-Related Acute Kidney InjuryNathan H Raines, Matthew D Cheung, Landon S Wilson, et al.
The Journal of Clinical Investigation|January 29, 2019
Intact HIV-1 proviruses accumulate at distinct chromosomal positions during prolonged antiretroviral therapyKevin B Einkauf, Guinevere Q Lee, Ce Gao, et al.
The Journal of Infectious Diseases|October 14, 2024
Viral and Symptom Rebound Following Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Therapy in a Randomized Placebo-Controlled TrialKara W Chew, Brooke McGinley, Carlee Moser, et al.
Eclinicalmedicine|September 10, 2024
Post-acute COVID-19 outcomes including participant-reported long COVID: amubarvimab/romlusevimab versus placebo in the ACTIV-2 trialTeresa H Evering, Carlee Moser, Nikolaus Jilg, et al.
Mbio|February 24, 2021
Phospholipid Metabolism Is Associated with Time to HIV Rebound upon Treatment InterruptionLeila B Giron, Emmanouil Papasavvas, Xiangfan Yin, et al.
Medrxiv : the Preprint Server for Health Sciences|June 14, 2021
Virologic features of SARS-CoV-2 infection in childrenLael M Yonker, Julie Boucau, James Regan, et al.
The Journal of Infectious Diseases|October 14, 2021
Virologic Features of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in ChildrenLael M Yonker, Julie Boucau, James Regan, et al.
The Journal of Antimicrobial Chemotherapy|March 11, 2021
Impact of pre-existing drug resistance on risk of virological failure in South AfricaJonathan Z Li, Natalia Stella, Manish C Choudhary, et al.
Pageof 27